Author Beth Macy’s latest book, “Raising Lazarus: Hope, Justice, and the Future of America’s Overdose Crisis,” documents those who are on the ground working in harm reduction across the United States. Woven throughout these profiles, Macy also dives into the intricacies of the litigation aimed at holding Purdue Pharma and the Sackler family accountable.
Two Washington Post journalists say pharmaceutical companies collaborated with each other — and with lawyers and lobbyists — to create laws to protect the industry. Their new book is American Cartel.
The Sacklers, who own Purdue Pharma, maker of Oxycontin, have maintained they did nothing wrong. People who lost loved ones and years of their lives to opioid addiction believe otherwise.
People who were addicted to OxyContin or lost loved ones who were addicted to the drug expect very little in compensation from the multibillion-dollar Purdue Pharma bankruptcy settlement.
The DOJ is seeking to block implementation of any part of the Purdue Pharma bankruptcy deal until legal challenges are settled. The deal granted Sackler family members immunity from opioid lawsuits.
The decision by a federal bankruptcy judge grants members of the family who own Purdue Pharma, maker of OxyContin, sweeping protection from any liability for the opioid crisis.
With a federal judge poised to approve Purdue Pharma's controversial Chapter 11 plan, the company is working behind the scenes to preempt a legal challenge by the DOJ.
In the Purdue Pharma bankruptcy trial now underway, scrutiny has focused on the Sacklers' demand for immunity from opioid lawsuits that would extend to a vast network of individuals and businesses.
The Purdue Pharma bankruptcy process has focused on financial compensation to creditors, but court records include heartrending personal letters from families ravaged by Oxycontin.
Two divisions of the DOJ argue the deal improperly shelters members of the Sackler family and their associates from liability. States are finalizing a separate deal with other opioid companies.